Detalhe da pesquisa
1.
HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2.
Eur J Cancer
; 159: 16-23, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34715459